Sab Biotherapeutics Stock Filter Stocks by Fundamentals
| SABS Stock | USD 1.62 0.02 1.25% |
SAB Biotherapeutics fundamentals help investors to digest information that contributes to SAB Biotherapeutics' financial success or failures. It also enables traders to predict the movement of SAB Stock. The fundamental analysis module provides a way to measure SAB Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SAB Biotherapeutics stock.
SAB | Shares Owned by Insiders |
SAB Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in SAB Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of SAB Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing SAB Biotherapeutics' value.| Shares | First Premier Bank | 2024-12-31 | 19 K | Kestra Advisory Services, Llc | 2024-12-31 | 11.9 K | Northern Trust Corp | 2024-12-31 | 11.4 K | Ubs Group Ag | 2024-12-31 | 1.1 K | Tower Research Capital Llc | 2024-12-31 | 842 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 599 | Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 250 | Gs Investment Inc | 2024-12-31 | 200 | Advisor Group Holdings, Inc. | 2024-12-31 | 200 | Bvf Inc | 2024-12-31 | 917.8 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 459.2 K |
SAB Fundamentals
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Current Valuation | (11.11 M) | ||||
| Shares Outstanding | 9.23 M | ||||
| Shares Owned By Insiders | 19.15 % | ||||
| Shares Owned By Institutions | 28.68 % | ||||
| Number Of Shares Shorted | 67.69 K | ||||
| Price To Book | 0.40 X | ||||
| Price To Sales | 9.88 X | ||||
| Revenue | 2.24 M | ||||
| Gross Profit | (25.38 M) | ||||
| EBITDA | (38.13 M) | ||||
| Net Income | (42.19 M) | ||||
| Cash And Equivalents | 16.62 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 5.91 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 1.72 X | ||||
| Book Value Per Share | 4.00 X | ||||
| Cash Flow From Operations | (25.12 M) | ||||
| Short Ratio | 0.58 X | ||||
| Earnings Per Share | (6.30) X | ||||
| Target Price | 14.0 | ||||
| Number Of Employees | 57 | ||||
| Beta | 0.45 | ||||
| Market Capitalization | 14.95 M | ||||
| Total Asset | 83.94 M | ||||
| Retained Earnings | (90.06 M) | ||||
| Working Capital | 48.09 M | ||||
| Net Asset | 83.94 M |
About SAB Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.